Allergan Inc.
Since fall 2008, Allergan and Polyphor collaborate to develop PEM cytokine inhibitors for the treatment of conditions and diseases of the eye. Thereby the two companies aim to identify compounds optimally suited for local delivery to the eye in combination with Allergan’s proprietary drug delivery systems (DDS).

